Cancer therapeutics in yeast

Cancer Cell

Volumn 2, Issue 4, 2002, Pages 267-273

  Bjornsti, Mary Ann ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN;

BUDDING; CANCER; CANCER THERAPY; CELL ACTIVITY; DRUG MECHANISM; DRUG SENSITIVITY; DRUG TARGETING; FUNGAL GENETICS; GENE IDENTIFICATION; GENE INTERACTION; GENE MUTATION; GENETIC SCREENING; LETHALITY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SACCHAROMYCES CEREVISIAE; YEAST; BIOLOGICAL MODEL; DRUG EFFECT; ENZYMOLOGY; GENETICS; HUMAN; NEOPLASM;

SACCHAROMYCES CEREVISIAE; SACCHAROMYCETALES;

ANTINEOPLASTIC AGENTS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; SACCHAROMYCES CEREVISIAE;

EID: 0036780368     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(02)00160-5     Document Type: Review

References (45)

1. Amatruda, J.F., Shepard, J.L., Stern, H.M., and Zon, L.I. (2002). Zebrafish as a cancer model system. Cancer Cell 1, 229-231.
2. Ball, C.A., Jin, H., Sherlock, G., Weng, S., Matese, J.C., Andrada, R., Binkley, G., Dolinski, K., Dwight, S.S., Harris, M.A., et al. (2001). Saccharomyces Genome Database provides tools to survey gene expression and functional analysis data. Nucleic Acids Res. 29, 80-81.
3. Bennett, C.B., Lewis, L.K., Karthikeyan, G., Lobachev, K.S., Jin, Y.H., Sterling, J.F., Snipe, J.R., and Resnick, M.A. (2001). Genes required for ionizing radiation resistance in yeast. Nat. Genet. 29, 426-434.
4. Birrell, G.W., Brown, J.A., Wu, H.I., Giaever, G., Chu, A.M., Davis, R.W., and Brown, J.M. (2002). Transcriptional response of Saccharomyces cerevisiae to DNA-damaging agents does not identify the genes that protect against these agents. Proc. Natl. Acad. Sci. USA 99, 8778-8783.
5. Cherry, J.M., Ball, C., Weng, S., Juvik, G., Schmidt, R., Adler, C., Dunn, B., Dwight, S., Riles, L., Mortimer, R.K., and Botstein, D. (1997). Genetic and physical maps of Saccharomyces cerevisiae. Nature 387, 67-73.
6. Christianson, T.W., Sikorski, R.S., Dante, M., Shero, J.H., and Hieter, P. (1992). Multifunctional yeast high-copy-number shuttle vectors. Gene 110, 119-122.
7. Csank, C., Costanzo, M.C., Hirschman, J., Hodges, P., Kranz, J.E., Mangan, M., O'Neill, K., Robertson, L.S., Skrzypek, M.S., Brooks, J., and Garrels, J.I. (2002). Three yeast proteome databases: YPD, PombePD, and CalPD (MycoPathPD). Methods Enzymol. 350, 347-373.
8. Dean, M., Rzhetsky, A., and Allikmets, R. (2001). The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 11, 1156-1166.
9. Dwight, S.S., Harris, M.A., Dolinski, K., Ball, C.A., Binkley, G., Christie, K.R., Fisk, D.G., Issel-Tarver, L., Schroeder, M., Sherlock, G., et al. (2002). Saccharomyces Genome Database (SGD) provides secondary gene annotation using the Gene Ontology (GO). Nucleic Acids Res. 30, 69-72.
10. Fiorani, P., and Bjornsti, M.-A. (2000). Mechanisms of DNA topoisomerase I-induced cell killing in the yeast Saccharomyces cerevisiae. Ann. N Y Acad. Sci. 922, 65-75.
11. Forsburg, S.L. (2001). The art and design of genetic screens: yeast. Nat. Rev. Genet. 2, 659-668.
12. Funk, M., Niedenthal, R., Mumberg, D., Brinkmann, K., Ronicke, V., and Henkel, T. (2002). Vector systems for heterologous expression of proteins in Saccharomyces cerevisiae. Methods Enzymol. 350, 248-257.
13. Giaever, G., Shoemaker, D.D., Jones, T.W., Liang, H., Winzeler, E.A., Astromoff, A., and Davis, R.W. (1999). Genomic profiling of drug sensitivities via induced haploinsufficiency. Nat. Genet. 21, 278-283.
14. Giaever, G., Chu, A.M., Ni, L., Connelly, C., Riles, L., Veronneau, S., Dow, S., Lucau-Danila, A., Anderson, K., Andre, B., et al. (2002). Functional profiling of the Saccharomyces cerevisiae genome. Nature 418, 387-391.
15. Goffeau, A., Barrell, B.G., Bussey, H., Davis, R.W., Dujon, B., Feldmann, H., Galibert, F., Hoheisel, J.D., Jacq, C., Johnston, M., et al. (1996). Life with 6000 genes. Science 274, 563-567.
16. Heitman, J., Movva, N.R., and Hall, M.N. (1991). Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253, 905-909.
17. Hudson, D.F., Morrison, C., Ruchaud, S., and Earnshaw, W.C. (2002). Reverse genetics of essential genes in tissue-culture cells: 'dead cells talking'. Trends Cell Biol. 12, 281-287.
18. Issel-Tarver, L., Christie, K.R., Dolinski, K., Andrada, R., Balakrishnan, R., Ball, C.A., Binkley, G., Dong, S., Dwight, S.S., Fisk, D.G., et al. (2002). Saccharomyces Genome Database. Methods Enzymol. 350, 329-346.
19. Jin, C., and Reed, J.C. (2002). Yeast and apoptosis. Nat. Rev. Mol. Cell Biol. 3, 453-459.
20. Johnston, M., Riles, L., and Hegemann, J.H. (2002). Gene disruption. Methods Enzymol. 350, 290-315.
21. Kang, J.J., Schaber, M.D., Srinivasula, S.M., Alnemri, E.S., Litwack, G., Hall, D.J., and Bjornsti, M.-A. (1999). Cascades of mammalian caspase activation in the yeast Saccharomyces cerevisiae. J. Biol. Chem. 274, 3189-3198.
22. Kauh, E.A., and Bjornsti, M.-A. (1995). SCT1 mutants suppress the camptothecin sensitivity of yeast cells expressing wild-type DNA topoisomerase I. Proc. Natl. Acad. Sci. USA 92, 6299-6303.
23. Kolaczkowska, A., and Goffeau, A. (1999). Regulation of pleiotropic drug resistance in yeast. Drug Resist Update 2, 403-414.
24. Kumar, A., and Snyder, M. (2001). Emerging technologies in yeast genomics. Nat. Rev. Genet. 2, 302-312.
25. Lawrence, C.W. (2002). Classical mutagenesis techniques. Methods Enzymol. 350, 189-199.
26. Le Crom, S., Devaux, F., Marc, P., Zhang, X., Moye-Rowley, W.S., and Jacq, C. (2002). New insights into the pleiotropic drug resistance network from genome-wide characterization of the YRR1 transcription factor regulation system. Mol. Cell. Biol. 22, 2642-2649.
27. Lengronne, A., Pasero, P., Bensimon, A., and Schwob, E. (2001). Monitoring S phase progression globally and locally using BrdU incorporation in TK(+) yeast strains. Nucleic Acids Res. 29, 1433-1442.
28. Liu, H. (2002). Constructing yeast libraries. Methods Enzymol. 350, 72-86.
29. Longtine, M.S., McKenzie, A., 3rd, Demarini, D.J., Shah, N.G., Wach, A., Brachat, A., Philippsen, P., and Pringle, J.R. (1998). Additional modules for versatile and economical PCR-based gene deletion and modification in Saccharomyces cerevisiae. Yeast 14, 953-961.
30. Ma, D. (2001). Applications of yeast in drug discovery. Prog. Drug Res. 57, 117-162.
31. Madeo, F., Engelhardt, S., Herker, E., Lehmann, N., Maldener, C., Proksch, A., Wissing, S., and Frohlich, K.U. (2002). Apoptosis in yeast: a new model system with applications in cell biology and medicine. Curr. Genet. 41, 208-216.
32. Measday, V., and Hieter, P. (2002). Synthetic dosage lethality. Methods Enzymol. 350, 316-326.
33. Nitiss, J., and Wang, J.C. (1988). DNA topoisomerase-targeting antitumor drugs can be studied in yeast. Proc. Natl. Acad. Sci. USA 85, 7501-7505.
34. Nitiss, J.L., and Wang, J.C. (1991). Yeast as a genetic system in the dissection of the mechanism of cell killing by topoisomerase-targeting anticancer drugs. In DNA Topoisomerases in Cancer, M. Potmesil and K.W. Kohn, eds.(Oxford: Oxford University Press), pp. 77-92.
35. Paddison, P.J., and Hannon, G.J. (2002). RNA interference: the new somatic cell genetics? Cancer Cell 2, 17-23.
36. Phizicky, E.M., and Fields, S. (1995). Protein-protein interactions: methods for detection and analysis. Microbiol. Rev. 59, 94-123.
37. Pringle, J.R., and Hartwell, L.H. (1981). The Saccharomyces cerevisiae cell cycle. In The Molecular Biology of the Yeast Saccharomyces, J.N. Strathern, E.W. Jones, and J.R. Broach, eds. (Cold Spring Harbor, NY: Cold Spring Harbor Laboratory), pp. 97-142.
38. Reid, R.J., Fiorani, P., Sugawara, M., and Bjornsti, M.-A. (1999). CDC45 and DPB11 are required for processive DNA replication and resistance to DNA topoisomerase I-mediated DNA damage. Proc. Natl. Acad. Sci. USA 96, 11440-11445.
39. Reid, R.J.D., Kauh, E.A., and Bjornsti, M.-A. (1997). Camptothecin sensitivity is mediated by the pleiotropic drug resistance network in yeast. J. Biol. Chem. 272, 12091-12099.
40. Reid, R.J.D., Benedetti, P., and Bjornsti, M.-A. (1998). Yeast as a model organism for studying the actions of DNA topoisomerase-targeted drugs. Biochim. Biophys. Acta 1400, 289-300.
41. Rothstein, R. (1991). Targeting, disruption, replacement, and allele rescue: Integrative DNA transformation in yeast. Methods Enzymol. 194, 281-301.
42. Sherman, F. (2002). Getting started with yeast. Methods Enzymol. 350, 3-41.
43. Shoemaker, D.D., Lashkari, D.A., Morris, D., Mittmann, M., and Davis, R.W. (1996). Quantitative phenotypic analysis of yeast deletion mutants using a highly parallel molecular bar-coding strategy. Nat. Genet. 14, 450-456.
44. Sikorski, R.S., and Hieter, P. (1989). A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in Saccharomyces cerevisiae. Genetics 122, 19-27.
45. Simon, J.A., Szankasi, P., Nguyen, D.K., Ludlow, C., Dunstan, H.M., Roberts, C.J., Jensen, E.L., Hartwell, L.H., and Friend, S.H. (2000). Differential toxicities of anticancer agents among DNA repair and checkpoint mutants of Saccharomyces cerevisiae. Cancer Res. 60, 328-333.